Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -4.49% | -0.54% |
2022 | Novelion Therapeutics Inc. Announces Final Cash Distribution, Payable on or About March 31, 2022 | CI |
2020 | Novelion Therapeutics Inc. Announces Management Changes | CI |
Chart calendar Novelion Therapeutics Inc.
Upcoming events on Novelion Therapeutics Inc.
No events available
Past events on Novelion Therapeutics Inc.
2019-09-18 | Shareholders Meeting |
2019-05-06 | Q1 2019 Earnings Release |
2019-03-13 | FY 2018 Earnings Release |
2018-11-08 | Q3 2018 Earnings Release |
2018-08-09 08:30 am | Annual General Meeting |
2018-08-06 | Interim 2018 Earnings Release |
2018-06-25 12:00 pm | American Diabetes Association Scientific Sessions - Abstract Number: 296-LB |
2018-05-09 | Q1 2018 Earnings Release |
2018-03-14 | FY 2017 Earnings Release |
2017-11-08 | Q3 2017 Earnings Release |
Annual results
Fiscal Period | December | 2014 | 2015 | 2016 | 2017 | 2018 |
---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 153 149 2.55% | 138 132 4.6% | 130 131 -0.13% |
EBITDA Million USD | Released Forecast Spread | -30,6 -5,90 -418.54% | -22,8 -24,1 5.52% | -36,5 -38,1 4.31% | -21,0 -28,8 26.92% | -8,97 -9,70 7.54% |
EBIT Million USD | Released Forecast Spread | -32,2 -25,8 -24.75% | -23,3 -24,4 4.26% | -38,9 -87,8 55.76% | -86,8 -58,6 -48.14% | 0,00 0,00 - |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -4,20 -24,4 82.77% | -23,0 -24,1 4.45% | -52,8 0,00 - | -126 -130 3.22% | 0,00 0,00 - |
Net income Million USD | Released Forecast Spread | -4,07 -24,4 83.33% | -23,0 -24,1 4.42% | -53,1 -95,7 44.56% | -127 -81,8 -54.82% | 0,00 0,00 - |
EPS USD | Released Forecast Spread | -0,40 -2,70 85.19% | -2,20 -2,30 4.35% | -4,70 -3,24 -44.93% | -6,81 -7,06 3.54% | -5,76 -5,63 -2.31% |
Announcement Date | 26/02/15 | 25/02/16 | 15/03/17 | 15/03/18 | 14/03/19 |
Past sector events for Novelion Therapeutics Inc.
- Stock Market
- Equities
- NVLNF Stock
- Calendar Novelion Therapeutics Inc.